Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic Melanoma

Next Previous
Trial Profile

Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic Melanoma

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AVMEL 1 (Primary) ; Granulocyte macrophage colony stimulating factor; Programmed cell death-1 receptor antagonists
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms AV-MEL-1 trial
  • Sponsors AiVita Biomedical

    • Most Recent Events

    • 16 Jan 2019 According to an AiVita Biomedical media release, the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the conduct of this trial.
    • 03 Jan 2019 Planned initiation date changed from 1 Jan 2019 to 1 Jun 2019.
    • 22 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top